Cargando…
The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
Background: In recent years, there has been a growing interest in telemedicine initiatives that maximize outcomes, reduce healthcare costs, and improve quality. The COVID-19 pandemic reduced healthcare access for many patients, including those undergoing chemotherapy, and thus accelerated these init...
Autores principales: | Runge, John S., Brown, Anna B., Phillips, Tycel J., Kaminski, Mark S, Carty, Shannon A., Wilcox, Ryan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356308/ http://dx.doi.org/10.1182/blood-2020-134151 |
Ejemplares similares
-
Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection
por: Lopez, Carlos A, et al.
Publicado: (2020) -
An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022) -
A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients
por: Farmer, Isabel, et al.
Publicado: (2020) -
Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic
por: Mussetti, Alberto, et al.
Publicado: (2020) -
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)